SeraCare says Nasdaq delisting stayed

By Ted A. Knutson

Washington, Jan. 9 - SeraCare Life Sciences, Inc. said Monday Nasdaq has stayed a staff recommendation that the company's shares be delisted pending an appeal hearing on Feb. 2 and a final written decision by the Nasdaq Listing Qualifications Panel.

In December the Nasdaq staff recommended SeraCare be delisted for its failure to timely file a 10-K for its fiscal year ended Sept. 30. SeraCare said the filing was being delayed because the company's independent auditors raised concerns regarding SeraCare's financial statements and accounting documentation.

SeraCare is an Oceanside, Calif.-based biotechnology company.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.